AI-CVD vs iPredict Eye Screening

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

AI-CVD

by HeartLung AI

iPredict Eye Screening

by iHealthScreen

AI Verdict

Tool A specializes in opportunistic screening for cardiovascular and multisystem diseases by analyzing existing CT scans, providing direct anatomical and density-based measurements. Tool B primarily focuses on screening for retinal diseases like AMD, DR, and Glaucoma using retinal images, while also offering risk prediction for systemic conditions such as stroke and heart attack. Although both aim for early disease detection and touch upon cardiovascular health, their distinct data sources (CT vs. retinal scans) and primary clinical applications make them complementary rather than direct competitors.

Choose AI-CVD if…

Choose AI-CVD if your primary goal is to opportunistically identify hidden cardiovascular and multisystem disease risks in patients who have already undergone existing CT scans for other clinical indications. This tool is ideal for leveraging pre-existing imaging data to perform automated, quantitative analysis without requiring additional radiation, contrast, or workflow disruption, focusing on metrics like coronary artery calcium scoring and cardiac chamber volumetry.

View AI-CVD →

Choose iPredict Eye Screening if…

Choose iPredict Eye Screening if you need a rapid, non-invasive AI-powered solution for screening patients for common retinal diseases like AMD, Diabetic Retinopathy, and Glaucoma, particularly in primary care or ophthalmology settings. This platform is also well-suited for providing quick risk predictions for systemic diseases such as stroke and heart attack, integrating seamlessly with EHR and telemedicine services.

View iPredict Eye Screening →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	AI-CVD	iPredict Eye Screening
Pricing	Unknown	Contact for pricing
Deployment	Unknown	Cloud-based (Software as a Medical Device), accessible in primary care settings, clinics, hospitals, and online for telemedicine and prediction apps.
BAA Available	Yes AI-estimated	Unknown
FDA Status	Cleared AI-estimated	Cleared AI-estimated
HIPAA	Yes AI-estimated	Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

AI-CVD

AI-CVD's primary advantage in usability stems from its opportunistic nature, requiring no additional patient imaging, radiation, contrast, or workflow disruption, as it analyzes existing CT scans. While iPredict Eye Screening is fast and easy to operate with an advanced touchscreen interface, it still necessitates a dedicated screening process with new image acquisition.

Clinical Value

AI-CVD

AI-CVD demonstrates superior clinical value by leveraging existing CT scans for comprehensive opportunistic screening across ten FDA-cleared measurement domains, including cardiovascular, metabolic, and skeletal risks. This broad, passive detection of hidden health risks in a large patient population offers a significant advantage in early intervention and preventive care.

Pricing & Value

iPredict Eye Screening

iPredict Eye Screening offers greater pricing transparency by providing an estimated per-patient cost and explicitly stating a Software as a Service (SaaS) model. This allows potential customers to better understand the financial commitment and evaluate the value proposition compared to AI-CVD, which only states 'contact for pricing'.

Enterprise Readiness

iPredict Eye Screening

iPredict Eye Screening explicitly states HIPAA compliance and offers integration with Electronic Health Records (EHR) and telemedicine services, indicating a robust design for enterprise adoption and interoperability. While AI-CVD is cloud-deployed and FDA-cleared, its compliance statements for BAA and HIPAA are less definitive, requiring direct vendor contact.

Innovation

AI-CVD

AI-CVD's innovation is particularly impactful by transforming routinely acquired CT scans into a comprehensive opportunistic screening platform for a wide array of cardiovascular and multisystem diseases, maximizing the value of existing data without additional patient burden. This approach to uncovering hidden health risks on a population scale represents a significant paradigm shift in preventive care.

Support & Docs

Tie

Both companies provide clear contact information and have sections on their websites (e.g., 'Knowledge Center' for Tool A, 'Media & Publications' for Tool B) that suggest resources are available for users. Neither explicitly details a comprehensive public support portal or extensive documentation library, which is typical for B2B healthcare AI solutions requiring direct vendor engagement.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	AI-CVD	iPredict Eye Screening
Name	AI-CVD	iPredict Eye Screening
Company	HeartLung Corporation	iHealthScreen
Description	FDA-cleared, AI-powered quantitative imaging platform that performs opportunistic screening for cardiovascular and multisystem diseases using existing CT scans, enabling early detection of hidden health risks.	FDA-cleared AI-powered screening tool for age-related macular degeneration (AMD) in patients aged 50 years and older, alongside screening for Diabetic Retinopathy (DR) and Glaucoma. The platform also provides risk prediction for systemic diseases like stroke and heart attack, integrating with EHR and telemedicine services.
Key Specialties	Cardiology, Pulmonology, Radiology	Family Medicine, Internal Medicine, Ophthalmology
Core Functionality	Automated CT-derived anatomical and density-based measurements for opportunistic screening from existing chest and abdominal CT scans. Includes Coronary Artery Calcium (CAC) scoring, aortic/mitral valve calcium analysis, cardiac chamber volumetry, epicardial fat volumetry, and aorta/pulmonary artery sizing.	AI-Based Screening for Diabetic Retinopathy (DR), Age-related Macular Degeneration (AMD), and Glaucoma using retinal images. Also offers Electronic Health Record (EHR) Solutions, AI-Based Telemedicine Service, Image Analyzer for Retinal Vessel, Retinal Pathology, and OCT Inspector, and Online Health Risk Prediction System for Diabetic, Stroke, and Heart Attack patients.
Additional Benefits/Features	No additional imaging, radiation, contrast, or workflow disruption. Can identify risks for coronary heart disease, heart failure, atrial fibrillation, stroke, osteoporosis, liver steatosis, and diabetes.	Fast results (test completed in less than 5 minutes, report in under 60 seconds), high accuracy (approximately 95% on average), easy to operate, non-invasive, with an advanced touchscreen interface.

Videos

Demos, reviews, and walkthroughs featuring AI-CVD and iPredict Eye Screening.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

What types of diseases do these tools screen for, and what imaging modalities do they utilize?

AI-CVDu00ae performs opportunistic screening for cardiovascular and multisystem diseases, such as coronary heart disease, heart failure, stroke, osteoporosis, liver steatosis, and diabetes, by analyzing existing chest and abdominal CT scans. In contrast, iPredict Eye Screening screens for age-related macular degeneration (AMD) in patients 50 and older, diabetic retinopathy (DR), and glaucoma, along with providing risk prediction for systemic diseases like stroke and heart attack, all using retinal images captured with a color fundus camera.

How do these tools integrate into a physician's existing workflow, and what are the patient requirements for each?

AI-CVDu00ae is designed for opportunistic screening from existing CT scans, meaning it requires no additional imaging, radiation, contrast, or workflow disruption. iPredict Eye Screening is a non-invasive tool that integrates with EHR and telemedicine services, with the test completed in less than 5 minutes and a report generated in under 60 seconds, primarily for patients aged 50 years and older for AMD screening.

What specific cardiovascular insights does AI-CVD provide compared to the systemic risk predictions offered by iPredict Eye Screening?

AI-CVDu00ae provides automated CT-derived anatomical and density-based measurements, including Coronary Artery Calcium (CAC) scoring, aortic wall, aortic valve, and mitral valve calcium analysis, cardiac chamber volumetry, epicardial fat volumetry, and aorta and pulmonary artery sizing. iPredict Eye Screening offers online health risk prediction for systemic diseases such as stroke and heart attack, in addition to its primary focus on retinal disease screening.

Which medical specialties are these tools primarily designed for?

AI-CVDu00ae is primarily designed for Cardiology, Pulmonology, and Radiology specialties. iPredict Eye Screening is intended for use in Family Medicine, Internal Medicine, and Ophthalmology.

Are there any differences in the pricing structure or transparency between AI-CVD and iPredict Eye Screening?

AI-CVDu00ae's pricing information is available upon contacting the vendor. iPredict Eye Screening offers a per-patient screening on a Software as a Service (SaaS) model, with an estimated cost of $10-$20 per patient, which is approximately 20%-40% of Medicare/commercial payor reimbursement.

Beyond disease detection, what additional features do these tools offer, such as EHR integration or telemedicine capabilities?

AI-CVDu00ae focuses on automated CT-derived measurements for early disease detection without workflow disruption. iPredict Eye Screening offers Electronic Health Record (EHR) solutions and AI-Based Telemedicine Service, along with an Image Analyzer for Retinal Vessel, Retinal Pathology, and OCT Inspector.